Hemispherx Biopharma Provides Corporate Update On Various Strategic Initiatives

PHILADELPHIA, June 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE
AMEX:HEB) announced that a corporate update on operations has been provided on
June 12, 2009 and can be accessed at BioMedReports.com. The interview provides
current information on both regulatory and clinical fronts on the company's
platform technology, including Ampligen(r), an experimental therapeutic, and
Alferon-N, a FDA approved product for treatment of refractory HPV, now being
pursued as a potential treatment for pandemic influenza. To access the full
interview, go to:
http://biomedreports.com/articles/most-popular/1314-exclusive-interview-dr-willi
m-a-carter-ceo-hemispherx-biopharma-inc-amexheb.html

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the
manufacture and clinical development of new drug entities for treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(r) (FDA approved for a category of sexually transmitted diseases)
and the experimental therapeutics, Ampligen(r) and Oragens. Ampligen(r) and
Oragens represent experimental RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform technology includes large and small agent components for potential
treatment of various severely debilitating and life threatening diseases.
Hemispherx has in excess of 50 issued patents comprising its core intellectual
property estate and a fully commercialized product (Alferon N Injection(r)). The
Company wholly owns and exclusively operates a GMP certified manufacturing
facility in the United States for commercial products. For more information
please visit www.hemispherx.net.

Information contained in this news release other than historical information,
should be considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition, changing market conditions, change in laws and regulations
affecting these industries and numerous other factors discussed in this release
and in the Company's filings with the Securities and Exchange Commission. Any
specifically referenced investigational drugs and associated technologies of the
Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in
nature and as such are not designated safe and effective by a regulatory
authority for general use and are legally available only through clinical trials
with the referenced disorders. The forward-looking statements represent the
Company's judgment as of the date of this release. The Company disclaims,
however, any intent or obligation to update these forward-looking statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(r) do not imply that the product will ever be specifically approved
commercially for these other treatment indications; similarly, the completion of
the NDA filing process with Ampligen(r) does not imply that the product will
ever be approved commercially.

-0-
CONTACT: Hemispherx Biopharma, Inc.
Company/Investor Contact:
Dianne Will
518-398-6222
ir@hemispherx.net